This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Applied Genetic Technologies 過去の業績

過去基準チェック /06

主要情報

-39.8%

収益成長率

-21.1%

EPS成長率

Biotechs 業界の成長	-14.6%
収益成長率	-57.4%
株主資本利益率	-398.0%
ネット・マージン	-21,610.5%
前回の決算情報	30 Sep 2022

Recent updates

収支内訳

Applied Genetic Technologies の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

DB:2GT 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費	研究開発費
30 Sep 22	0	-70	17	28
30 Jun 22	0	-69	17	28
31 Mar 22	1	-63	17	25
31 Dec 21	1	-63	16	23
30 Sep 21	1	-60	15	22
30 Jun 21	1	-58	15	21
31 Mar 21	0	-60	14	21
31 Dec 20	0	-57	14	21
30 Sep 20	2	-50	14	27
30 Jun 20	2	-46	14	21
31 Mar 20	3	-42	13	21
31 Dec 19	24	-19	13	29
30 Sep 19	28	-15	13	20
30 Jun 19	42	-2	13	19
31 Mar 19	47	2	13	2
31 Dec 18	29	-18	14	1
30 Sep 18	28	-19	14	5
30 Jun 18	24	-21	14	0
31 Mar 18	27	-18	14	27
31 Dec 17	32	-11	13	15
30 Sep 17	38	-4	12	15
30 Jun 17	39	0	11	15
31 Mar 17	43	6	11	11
31 Dec 16	47	10	10	11
30 Sep 16	48	11	10	11
30 Jun 16	47	-1	10	11
31 Mar 16	36	-12	10	0
31 Dec 15	24	-20	11	0

質の高い収益: 2GT is currently unprofitable.

利益率の向上: 2GT is currently unprofitable.

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: 2GT is unprofitable, and losses have increased over the past 5 years at a rate of 39.8% per year.

成長の加速: Unable to compare 2GT's earnings growth over the past year to its 5-year average as it is currently unprofitable

収益対業界: 2GT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-15.1%).

株主資本利益率

高いROE: 2GT has a negative Return on Equity (-398.02%), as it is currently unprofitable.

This company listing is no longer active

Applied Genetic Technologies 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Applied Genetic Technologies Corporation to Report Q2, 2022 Results on Feb 14, 2022

Applied Genetic Technologies Corporation to Report Q2, 2021 Results on Feb 11, 2021

Full year earnings released - €2.17 loss per share

Applied Genetic Technologies Corporation to Report Q4, 2020 Results on Sep 09, 2020

Recent updates

Applied Genetic Technologies Corporation(NasdaqGM:AGTC) dropped from NASDAQ Composite Index

Syncona Limited (LSE:SYNC), a fund managed by Syncona Investment Management Limited completed the acquisition of Applied Genetic Technologies Corporation (NasdaqGM:AGTC).

Applied Genetic Technologies Corporation announced delayed 10-Q filing

Insufficient new directors

Syncona Limited (LSE:SYNC), a fund managed by Syncona Investment Management Limited, entered into a definitive agreement to acquire Applied Genetic Technologies Corporation (NasdaqGM:AGTC) for $23.3 million.

Applied Genetic Technologies Corporation has completed a Follow-on Equity Offering.

Applied Genetic Technologies Corporation has completed a Follow-on Equity Offering.

Applied Genetic Technologies Receives Non-Compliance Notice from Nasdaq

Applied Genetic Technologies Corporation Announces Executive Appointments

AGTC Announces Positive Three-Month Interim Results from Skyline Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa

Applied Genetic Technologies Corporation Presents Positive 18-Month Data from Ongoing Phase 1/2 Clinical Study of AGTC-501 At the Association for Research in Vision and Ophthalmology 2022 Annual Meeting

Insufficient new directors

Insufficient new directors

Ivana Magovcevic-Liebisch Resigns from Board of Directors and Each Committee of Which She Was A Member of Applied Genetic Technologies Corporation, Effective March 9, 2022

Insufficient new directors

Applied Genetic Technologies Reports Updated Interim Three-Month Pediatric Results and Additional Adult Safety Results Out to as Long as 24 Months from Its Ongoing Phase 1/2 Dose Escalation Study of AGTC-401

Applied Genetic Technologies Corporation to Report Q2, 2022 Results on Feb 14, 2022

AGTC Exceeds Enrollment Target in SKYLINE Trial of AGTC-501 for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

Insufficient new directors

Insufficient new directors

Applied Genetic Technologies Corporation Announces Ongoing Clinical Trials in achromatopsia and X-Linked Retinitis Pigmentosa at the Fourteenth International Symposium on Retinal Degeneration

Applied Genetic Technologies Corporation(NasdaqGM:AGTC) dropped from Russell 3000E Index

Applied Genetic Technologies Corporation Reports 12-Month Data from Its Ongoing Phase 1/2 Achromatopsia Clinical Trials Showing Biologic Activity in Patients with Mutations in the ACHM B3 Gene

Otonomy, Inc. and Applied Genetic Technologies Corporation Present Preclinical Proof-Of-Concept Results for Oto-825 Gene Therapy At ASGCT Annual Meeting

Applied Genetic Technologies Corporation Advances for Manufacturing its XLRP Gene Therapy Candidate in Two Abstracts at ASGCT

Applied Genetic Technologies Corporation Reports Additional Positive Data from the Ongoing X-Linked Retinitis Pigmentosa Phase 1/2 Clinical Trial

Agtc Clinical Investigators Provide Encore Presentation of Data from the Company’s Ongoing XLRP and Achromatopsia Phase 1/2 Trials

Revenue in line with expectations

Applied Genetic Technologies Corporation to Report Q2, 2021 Results on Feb 11, 2021

New 90-day low: €3.20

Applied Genetic Technologies Corporation has completed a Follow-on Equity Offering in the amount of $74.5 million.

New 90-day low: €3.30

New 90-day low: €3.94

Revenue in line with expectations

Applied Genetic Technologies Corporation Reports Additional Positive Data from its Phase 1/2 Clinical Trial in Patients with X-Linked Retinitis Pigmentosa

Applied Genetic Technologies Corporation Plans to Release 12-Month Data for Groups 1 Through 4 Evaluating Durability of Effect and Continued Safety and Interim Data of Groups 5 and 6 Evaluating Safety and Efficacy at Higher Doses for its Phase 1/2 Clinical Trial

Applied Genetic Technologies Corporation, Annual General Meeting, Dec 16, 2020

Applied Genetic Technologies Corporation Joins the My Retina Tracker® Program as A New Scientific Collaborator

New 90-day low: €4.14

Full year earnings released - €2.17 loss per share

Applied Genetic Technologies Corporation to Report Q4, 2020 Results on Sep 09, 2020

New 90-day low - €4.16

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06